The first two COVID-19 vaccines authorized for emergency use by the U.S. Food and Drug Administration (FDA) employed mRNA technology, which had never before been used in FDA-approved vaccines. A new study has found evidence that the immune response to such vaccines is both strong and potentially long-lasting.